Vesicovaginal Fistula: Causes, Symptoms, and Treatment Options — Cost, Top Hospitals & Success Rates | MyMedicPlus

A vesicovaginal fistula (VVF) is an abnormal epithelialised tract connecting the bladder (vesica) to the vagina, resulting in continuous involuntary leakage of urine through the vagina. It is one of the most socially devastating complications in obstetrics and gynaecology, causing constant wetness, recurrent infections, skin excoriation, and profound psychosocial consequences including social isolation, relationship breakdown, and depression.

The aetiology differs sharply by geography. In sub-Saharan Africa and South Asia, the overwhelming cause is obstructed labour: prolonged compression of the bladder base and anterior vaginal wall between the fetal head and maternal pubic symphysis during labour causes ischaemic necrosis and fistula formation. The UNFPA Campaign to End Fistula estimates that approximately 50,000–100,000 new obstetric fistulas occur annually worldwide, with a global backlog of 1–2 million women living with untreated fistulas. In high-income countries, the principal causes are iatrogenic: injury during pelvic surgery (most commonly total abdominal hysterectomy), radiation therapy for cervical or endometrial cancer, and malignant infiltration of the bladder wall.

Symptoms are typically pathognomonic: continuous, effortless leakage of urine vaginally, beginning acutely within hours (traumatic fistula) or after a latent period of 7–14 days (ischaemic necrosis post-labour or post-surgical). The diagnosis is confirmed by a positive dye test (methylene blue instilled into the bladder via urethral catheter; blue dye observed at the vagina), supplemented by cystoscopy, vaginoscopy, and imaging (CT urogram or MRI) to define fistula location, size, number, and to exclude ureteric involvement (ureterovaginal fistula can coexist).

VVF repair surgery addresses the fistula and its sequelae across the following clinical scenarios:

• Obstetric VVF: The most common form globally. Typically located in the anterior vaginal wall at the bladder base or trigone. Associated with chronic undernutrition, adolescent pregnancy, short maternal stature, and lack of access to emergency obstetric care. Often accompanied by urethral injury, vesicouterine fistula, or rectovaginal fistula, creating complex compound fistulas.
• Post-hysterectomy VVF: The most common aetiology in high-income countries, accounting for approximately 75% of VVF in the UK and US. The fistula typically appears at the vaginal vault, 7–14 days after total hysterectomy, when haematoma overlying an unrecognised bladder entry resolves and a communication opens. Incidence after benign hysterectomy is approximately 0.1–0.3%.
• Radiation-induced VVF: Occurs months to years after pelvic radiotherapy for cervical, endometrial, or rectal cancer. The surrounding tissues are ischaemic and poorly vascularised, making repair substantially more challenging than simple surgical VVF and often requiring interposition of a well-vascularised flap.
• Malignancy-related VVF: Direct invasion of the bladder wall by cervical, vaginal, or rectal carcinoma. Palliative management (urinary diversion) rather than surgical repair is typically appropriate.
• Post-traumatic VVF: Resulting from pelvic fracture, sexual violence, or foreign body injury — particularly relevant in conflict and post-conflict settings.

Complex fistulas — those that are large (>4 cm), circumferential, recurrent, radiation-induced, or associated with urethral or ureteric damage — require referral to a specialist fistula centre with multidisciplinary expertise in urogynaecology, colorectal surgery, and plastic surgery.

Patient selection and timing of repair are critical determinants of surgical success:

• Conservative management first — for small, early fistulas: Fistulas identified within the first 48–72 hours of formation that are small (<5 mm) and without surrounding tissue necrosis may close spontaneously with continuous Foley catheter drainage for 4–6 weeks. Success rates are reported at 10–20% in the published literature; this approach avoids surgery in a subset of patients and does not compromise later surgical repair if it fails.
• Timing of surgical repair — the central debate: Traditional teaching advocated waiting 3 months post-injury to allow oedema and inflammation to resolve and tissue planes to become clearly defined. Contemporary evidence — including data from high-volume fistula programmes — supports early repair (within 3 months) in well-selected patients with clean, non-irradiated tissues, provided active infection and necrosis have resolved. Early repair reduces the psychological burden and duration of incontinence. Radiation-induced fistulas should generally be deferred for 12 months post-radiation to allow maximal tissue stabilisation.
• Prerequisites for surgery: All active urinary tract infection must be treated and confirmed clear on culture before repair. Vaginal atrophy in post-menopausal women is treated with topical oestrogen for 6–8 weeks pre-operatively to improve tissue quality. Nutritional status should be optimised, particularly in women from low-income settings.
• Surgical eligibility: Medically fit for general or regional anaesthesia; no active malignancy at the fistula site; no uncontrolled radiation cystitis.

Multiple surgical approaches exist, selected based on fistula size, location, tissue quality, prior repair attempts, and available surgical expertise:

• Conservative management — Foley catheter drainage: Continuous bladder catheterisation for 4–6 weeks is the initial approach for small (<5 mm), early fistulas without surrounding necrosis. The catheter keeps the bladder collapsed, reduces hydrostatic pressure across the fistula, and allows some spontaneous closure. Anticholinergic medication reduces bladder spasms. Success is unpredictable but obviates surgery in 10–20% of cases.
• Transvaginal repair (primary approach): The most widely used approach for accessible, non-irradiated VVF. Performed in the lithotomy position. The fistula tract is excised or freshened, the vaginal epithelium is widely mobilised from the bladder wall, the bladder defect is closed in two watertight layers (mucosa and muscularis) using 3-0 polyglactin (Vicryl) sutures, and the vaginal wall is closed as a separate third layer in a non-overlapping fashion. A Foley catheter is left in situ for 10–14 days to prevent tension on the bladder closure.
• Latzko Partial Colpocleisis: A simplified transvaginal technique particularly useful for small post-hysterectomy VVF at the vaginal vault. The vaginal epithelium surrounding the fistula is denuded without excising the fistula tract itself; the denuded vaginal walls are sutured together in layers, effectively closing the vaginal vault around the fistula. Success rates are 90–95% for suitable cases; minimal blood loss and short operative time make it favourable for fragile patients.
• Transabdominal (O'Connor) technique: Used for high or complex VVF inaccessible vaginally, recurrent fistulas, or those requiring concurrent ureteric reimplantation. The bladder is bisected (bivalved) in the midline, the fistula identified and excised from both bladder and vagina, and each organ closed separately in layers. An interposition flap (omentum) is routinely interposed between the closures.
• Martius Flap (Bulbocavernosus Flap): A well-vascularised pedicled flap of bulbocavernosus muscle and labial fat pad, rotated through a subcutaneous tunnel to interpose between the bladder and vaginal closures. This brings a new blood supply to the repair site and is particularly valuable in radiation-induced fistulas, recurrent repairs, and cases with compromised local vascularity.
• Laparoscopic and robotic-assisted repair: Increasingly reported for post-hysterectomy VVF at experienced centres. Offers reduced blood loss, shorter hospitalisation, and faster return to normal activity compared with open transabdominal approaches, with equivalent closure rates in experienced hands.

Successful VVF repair is transformative in quality of life and social functioning:

• Continence restoration: Primary surgical repair of obstetric and post-surgical VVF achieves continence in 85–95% of cases at experienced fistula centres. Recurrent and radiation-induced fistulas have lower success rates (60–80%) but still offer substantial benefit.
• Social reintegration: For women in low-income settings, fistula closure frequently enables return to family life, employment, and social participation — outcomes that are central to the UNFPA global fistula programme mission. Studies document dramatic improvements in mental health, self-esteem, and marital and social relationships after successful repair.
• Freedom from continuous catheterisation: Before repair, many women require indwelling catheters, incontinence pads, or improvised measures — all burdensome and expensive. Successful repair eliminates this dependency.
• Preserved fertility: Transvaginal repair, Latzko colpocleisis, and minimally invasive techniques preserve uterine integrity and vaginal calibre, allowing subsequent pregnancy in women of reproductive age. Women should be counselled to deliver by elective caesarean section in future pregnancies to prevent recurrence.
• Infection prevention: Continuous urinary leakage causes chronic vaginal, perineal, and skin infections. Successful closure eliminates this source of morbidity.

VVF repair surgery carries both general surgical risks and fistula-specific complications:

Intra-operative risks:

• Haemorrhage: The bladder base and trigone are highly vascular; meticulous dissection and haemostasis are required. Blood transfusion is rarely needed but should be available for complex cases.
• Ureteric injury: In fistulas adjacent to or involving the trigone, the ureteric orifices are at risk. Ureteric catheters (stents) are routinely placed intra-operatively to identify and protect the ureters.
• Bowel injury: In transabdominal approaches or re-do surgery with dense adhesions.

Post-operative complications:

• Fistula recurrence: The most significant outcome risk. Reported recurrence rates are 5–15% at specialist centres for primary simple fistulas, rising to 20–40% for radiation-induced or recurrent VVF. Most recurrences become apparent within 4 weeks of catheter removal.
• Urinary tract infection: Common during the catheterisation period; treated with prophylactic or therapeutic antibiotics guided by urine cultures.
• Voiding dysfunction: Bladder capacity may be reduced after repair; incomplete bladder emptying or de novo urgency can follow closure of large fistulas that had been acting as the primary void pathway.
• Reduced vaginal calibre: Particularly after Latzko colpocleisis, which shortens and narrows the vaginal vault. This has implications for sexual function and future deliveries.
• Wound dehiscence: Failure of the vaginal closure suture line, more common in malnourished patients or with inadequate tissue mobilisation.

Post-operative care and monitoring are as critical as the surgery itself in achieving successful fistula closure:

• Urethral catheterisation: A silicone Foley catheter is maintained in the bladder for 10–14 days post-repair for simple transvaginal cases and 14–21 days after transabdominal repair. Continuous free drainage is essential; catheter blockage results in bladder overdistension that ruptures the repair. Patients must be educated to monitor catheter drainage and report any reduction in output.
• Trial of void: After catheter removal, a trial of void and post-void residual volume is measured. Some units perform a cystogram (fluoroscopic or CT) before catheter removal to confirm watertight closure before risking urine stress on the repair.
• Antibiotic prophylaxis: Trimethoprim or nitrofurantoin prophylaxis is standard throughout the catheterisation period and for 2–4 weeks after catheter removal.
• Activity restrictions: No sexual intercourse for 3 months post-repair. Avoid heavy lifting and straining for 6 weeks. Women should not be permitted to labour vaginally in future pregnancies — elective caesarean section is mandatory.
• Long-term urological follow-up: Urodynamic studies 3–6 months post-repair identify residual voiding dysfunction, detrusor overactivity, or stress incontinence that may benefit from further intervention. Bladder neck procedures or vaginal mesh operations may be needed in some patients.
• Psychological support: Women who have lived with obstetric fistula for years require structured psychosocial support during and after treatment to address depression, trauma, and social reintegration challenges — elements integral to UNFPA-supported fistula programmes.

Vesicovaginal fistula repair costs are influenced by fistula complexity, surgical approach, institutional context, and country:

• Sub-Saharan Africa and South Asia: Obstetric fistula repair is frequently provided free of charge or at minimal cost through UNFPA-supported fistula centres, government hospitals, and NGO-funded programmes in countries including Ethiopia, Nigeria, Tanzania, Niger, and Bangladesh. The Fistula Foundation and the United Nations Population Fund fund surgical missions and capacity-building programmes specifically to eliminate the cost barrier for poor women.
• India: Surgical repair at private gynaecology or urogynaecology centres costs approximately INR 30,000–100,000 (USD 360–1,200) depending on complexity and facility. Government hospital treatment under the RSBY and Pradhan Mantri Jan Arogya Yojana schemes may provide free or subsidised care.
• United Kingdom: NHS-funded repair at specialist urogynaecology centres is available for all eligible patients; no direct cost to the patient. Waiting times may be prolonged at busy centres.
• United States: Complex VVF repair at academic medical centres costs USD 8,000–20,000 or more including hospital stay, anaesthesia, and urological support. Health insurance typically covers surgical repair of post-surgical or radiation-induced VVF as a medically necessary procedure.

Additional considerations:

• Pre-operative investigations: CT urogram, cystoscopy, urodynamics
• Intra-operative ureteric stenting (if required)
• Extended hospital stay for complex or open transabdominal repair (5–7 days)
• Post-operative urodynamic assessment and physiotherapy
• Psychosocial support and rehabilitation programmes

For women who are not surgical candidates or for whom repair has failed, the following alternatives manage symptoms and maintain quality of life:

• Urinary diversion: Surgical diversion of urine away from the bladder — most commonly a Bricker ileal conduit (urostomy) or continent cutaneous diversion — is appropriate when the fistula is too large, too complex, or too radiation-damaged to repair, or when the patient has malignant disease. The fistula itself is not closed; urine is diverted before reaching the bladder. Accepted as definitive management for unresectable cancer-related VVF and for women who have failed multiple repair attempts.
• Bladder neck closure with suprapubic catheter: The urethra is surgically closed and a suprapubic catheter provides permanent urinary drainage. Considered when all reconstructive options have been exhausted and the woman cannot manage a stoma.
• Vaginal occlusion devices and pessaries: Specialised silicone occlusion plugs have been explored for temporary management while awaiting surgery but are not established standard of care for VVF management.
• Absorbent products and skincare: High-absorbency incontinence pads and barrier creams (zinc oxide, Cavilon) protect the perineal skin from urine scalding and are essential for women during the waiting period before surgery, during conservative management, or as palliative support.

For most women with simple post-surgical or obstetric VVF, surgical repair at a specialist centre remains the only treatment that can fully restore continence. Referral to a subspecialty urogynaecology or fistula centre — rather than treatment by a general gynaecologist — is associated with substantially higher success rates and lower recurrence, and should be strongly recommended for all cases.